Zaorsky NG - Search Results

1

Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.

Zaorsky NG, Shaikh T, Murphy CT, Hallman MA, Hayes SB, Sobczak ML, Horwitz EM. Zaorsky NG, et al. Cancer Treat Rev. 2016 Jul;48:50-60. doi: 10.1016/j.ctrv.2016.06.006. Epub 2016 Jun 17. Cancer Treat Rev. 2016. PMID: 27347670 Free PMC article. Review.

2

Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions.

Shen X, Zaorsky NG, Mishra MV, Foley KA, Hyslop T, Hegarty S, Pizzi LT, Dicker AP, Showalter TN. Shen X, et al. Among authors: zaorsky ng. Future Oncol. 2012 Jan;8(1):37-54. doi: 10.2217/fon.11.131. Future Oncol. 2012. PMID: 22149034 Review.

3

Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method.

Zaorsky NG, Li T, Devarajan K, Horwitz EM, Buyyounouski MK. Zaorsky NG, et al. Cancer. 2012 Nov 15;118(22):5535-43. doi: 10.1002/cncr.27597. Epub 2012 Apr 27. Cancer. 2012. PMID: 22544661 Free PMC article.

4

Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.

Zaorsky NG, Buyyounouski MK, Li T, Horwitz EM. Zaorsky NG, et al. Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e13-7. doi: 10.1016/j.ijrobp.2012.02.050. Epub 2012 May 30. Int J Radiat Oncol Biol Phys. 2012. PMID: 22652109 Free PMC article.

5

Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?

Zaorsky NG, Studenski MT, Dicker AP, Gomella L, Den RB. Zaorsky NG, et al. Cancer Treat Rev. 2013 May;39(3):212-8. doi: 10.1016/j.ctrv.2012.10.003. Epub 2012 Dec 4. Cancer Treat Rev. 2013. PMID: 23218442 Review.

6

Systematic review of hypofractionated radiation therapy for prostate cancer.

Zaorsky NG, Ohri N, Showalter TN, Dicker AP, Den RB. Zaorsky NG, et al. Cancer Treat Rev. 2013 Nov;39(7):728-36. doi: 10.1016/j.ctrv.2013.01.008. Epub 2013 Mar 1. Cancer Treat Rev. 2013. PMID: 23453861 Free PMC article. Review.

7

Multimodality therapy for patients with high-risk prostate cancer: current status and future directions.

Zaorsky NG, Trabulsi EJ, Lin J, Den RB. Zaorsky NG, et al. Semin Oncol. 2013 Jun;40(3):308-21. doi: 10.1053/j.seminoncol.2013.04.006. Semin Oncol. 2013. PMID: 23806496 Review.

8

The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?

Zaorsky NG, Raj GV, Trabulsi EJ, Lin J, Den RB. Zaorsky NG, et al. Semin Oncol. 2013 Jun;40(3):322-36. doi: 10.1053/j.seminoncol.2013.04.011. Semin Oncol. 2013. PMID: 23806497 Review.

9

Evolution of advanced technologies in prostate cancer radiotherapy.

Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Zaorsky NG, et al. Nat Rev Urol. 2013 Oct;10(10):565-79. doi: 10.1038/nrurol.2013.185. Epub 2013 Sep 10. Nat Rev Urol. 2013. PMID: 24018567 Review.

10

Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?

Zaorsky NG, Doyle LA, Hurwitz MD, Dicker AP, Den RB. Zaorsky NG, et al. Expert Rev Anticancer Ther. 2014 Jan;14(1):39-50. doi: 10.1586/14737140.2013.836303. Expert Rev Anticancer Ther. 2014. PMID: 24124755 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page